NewLimit raised $435 million in a Series C round at a $3B+ valuation to push an anti-aging program toward human testing. The financing, led by Founders Fund, includes participation from Thrive Capital and Lilly Ventures and draws in other investors such as Nat Friedman and Daniel Gross. The startup said it expects to begin a first clinical trial next year for its lead liver medicine, after faster-than-expected preclinical signal development. NewLimit described using a transcription-factor combination screening platform to identify a dosing-ready molecular approach carried in lipid nanoparticles. Company leadership said the program’s current plan is to initiate Phase 1 testing with patients who have fatty livers, followed by Phase 2 refinement in alcohol-related liver disease indications. While the company did not disclose the specific transcription factor identity, it characterized the candidate as a cell reprogramming effort intended to restore youthful functional capacity in aged tissue. The round places another well-capitalized longevity entrant into clinical execution and highlights continued investor appetite for transformative modalities that can reset disease-relevant biology.